Biothera

OverviewSuggest Edit

Biothera Pharmaceuticals Inc. is a mid clinical-stage biotechnology company advancing Imprime PGG, a first-in-class, systemically administered beta glucan PAMP (pathogen associated molecular pattern). Imprime PGG acts as an immunological “ignition switch,” triggering a robust, coordinated immune response to enhance the anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic antibodies (e.g., Avastin®), and tumor-targeting monoclonal antibodies (e.g., Erbitux®). Imprime PGG is the most advanced PAMP in immune-oncology, with a strong safety profile in 400+ patients and established proof of concept in single arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer (mCRC), and chronic lymphocytic leukemia (CLL). Imprime PGG has broad intellectual property protections, with more than 100 issued and pending patients in the US and internationally. Biothera Pharmaceuticals is a subsidiary of Biothera Holding Corp., a privately held company.
TypePrivate
Founded1997
HQRoseville, MN, US
Websitebiothera.com

Latest Updates

Employees (est.) (Apr 2021)41(-2%)
Cybersecurity ratingAMore

Key People/Management at Biothera

Richard Mueller

Richard Mueller

CEO
William Gacki

William Gacki

CFO
Steven Karel

Steven Karel

COO
Myra Patchen

Myra Patchen

CSO
Daniel Conners

Daniel Conners

Founder, President & Chairman
Show more

Biothera Office Locations

Biothera has an office in Roseville
Roseville, MN, US (HQ)
2825 Fairview Ave N
Show all (1)

Biothera Financials and Metrics

Summary Metrics

Founding Date

1997

Biothera total Funding

$5.1 m

Biothera latest funding size

$1.59 m

Time since last funding

6 years ago
Biothera's latest funding round in December 2014 was reported to be $1.6 m. In total, Biothera has raised $5.1 m
Show all financial metrics

Biothera Cybersecurity Score

Cybersecurity ratingPremium dataset

A

99/100

SecurityScorecard logo

Biothera Online and Social Media Presence

Embed Graph

Biothera News and Updates

Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center

- First Patient Dosed with LN-145 in Phase 2 Trial with MD Anderson for Treatment of Sarcomas and Ovarian Cancer -

Biothera Blogs

Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium

EAGAN, MN — December 11, 2019 — Biothera Pharmaceuticals, Inc. announced today that updated response and clinical benefit data from its ongoing Phase 2 study in chemo-refractory metastatic triple negative breast cancer (mTNBC) patients were presented during a Spotlight Session at the 2019 San Antoni…

Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium

EAGAN, MN — December 4, 2019 — Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in chemo-refractory metastatic triple negative breast…

Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and Overall Survival EAGAN, MN — November 8, 2019 — Biothera Pharmaceuticals, Inc. announced today immune …

Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting EAGAN, MN — November 5, 2019 — Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study i…

Tamas Mir Named Senior Vice President, Finance; CFO Andrew D. C. LaFrence Resigns to Pursue New Opportunity

EAGAN, MN — August 6, 2019 — Biothera Pharmaceuticals, Inc. today announced the appointment of Tamas Mir as Senior Vice President, Finance with responsibility for all finance functions, Human Resources and Information Technology.  Mr. Mir joined Biothera in 2012 as Corporate Controller and was promo…

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate (Three previous TNBC clinical studies with checkpoint inhibitor (CPI) monotherapies…
Show more

Biothera Frequently Asked Questions

  • When was Biothera founded?

    Biothera was founded in 1997.

  • Who are Biothera key executives?

    Biothera's key executives are Richard Mueller, William Gacki and Steven Karel.

  • How many employees does Biothera have?

    Biothera has 41 employees.

  • Who are Biothera competitors?

    Competitors of Biothera include AveXis, Juno Therapeutics and Idera Pharmaceuticals.

  • Where is Biothera headquarters?

    Biothera headquarters is located at 2825 Fairview Ave N, Roseville.

  • Where are Biothera offices?

    Biothera has an office in Roseville.

  • How many offices does Biothera have?

    Biothera has 1 office.